The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease
Jonathan H. Fox(University of Wyoming), Steven M. Hersch(Eisai (United States))
Cited by 96
Related Papers
Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease
|Alzheimer s Research & Therapy|2024|150
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial
|Journal of Clinical Medicine|2020|32
LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington’s Disease
|Journal of Huntington s Disease|2016|31